Drugs / NeoOVIV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07676890 | Jul 2026 → May 2028 expected | ovarian cancer | West China Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NeoOVIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07676890 ↗ |
| Modality | Messenger RNA (mRNA) | “NeoOVIV, a personalized mRNA-lipid nanoparticle vaccine” NCT07676890 ↗ |
| Route | Intramuscular | “by intramuscular injection” NCT07676890 ↗ |